Teva Pharmaceuticals Submits FDA Application for Monthly Schizophrenia Treatment

MT Newswires Live12-09

Teva Pharmaceuticals (TEVA) said Tuesday it has submitted a new drug application to the US Food and Drug Administration of its once-monthly olanzapine extended-release injection, TEV-749, to treat schizophrenia in adults.

The application is based on a phase 3 study in adults aged 18 to 64 that found that the long-acting under-the-skin treatment met efficacy and safety goals with results in line with oral version of the same drug, the company said.

The experimental injection uses Medincell's SteadyTeq technology to deliver a steady monthly dose of olanzapine, Teva said.

Shares of the company were up 1.7% in recent Tuesday trading.

Price: 28.77, Change: +0.44, Percent Change: +1.54

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590534058?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 23:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590534058","market":"hk","top_or_hot":-1,"title":"Teva Pharmaceuticals Submits FDA Application for Monthly Schizophrenia Treatment","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceuticals (TEVA) said Tuesday it has submitted a new drug application to the US Food and Drug Administration of its once-monthly olanzapine extended-release injection, TEV-749, to treat schizophrenia in adults.</p><p>The application is based on a phase 3 study in adults aged 18 to 64 that found that the long-acting under-the-skin treatment met efficacy and safety goals with results in line with oral version of the same drug, the company said.</p><p>The experimental injection uses <a href=\"https://laohu8.com/S/MDCLF\">Medincell</a>'s SteadyTeq technology to deliver a steady monthly dose of olanzapine, Teva said.</p><p>Shares of the company were up 1.7% in recent Tuesday trading.</p><p>Price: 28.77, Change: +0.44, Percent Change: +1.54</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceuticals Submits FDA Application for Monthly Schizophrenia Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceuticals Submits FDA Application for Monthly Schizophrenia Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-09 23:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceuticals (TEVA) said Tuesday it has submitted a new drug application to the US Food and Drug Administration of its once-monthly olanzapine extended-release injection, TEV-749, to treat schizophrenia in adults.</p><p>The application is based on a phase 3 study in adults aged 18 to 64 that found that the long-acting under-the-skin treatment met efficacy and safety goals with results in line with oral version of the same drug, the company said.</p><p>The experimental injection uses <a href=\"https://laohu8.com/S/MDCLF\">Medincell</a>'s SteadyTeq technology to deliver a steady monthly dose of olanzapine, Teva said.</p><p>Shares of the company were up 1.7% in recent Tuesday trading.</p><p>Price: 28.77, Change: +0.44, Percent Change: +1.54</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4596","symbol_name":"哈里斯概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590534058","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590534058","pubTimestamp":1765294504,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceuticals  said Tuesday it has submitted a new drug application to the US Food and Drug Administration of its once-monthly olanzapine extended-release injection, TEV-749, to treat schizophrenia in adults.The application is based on a phase 3 study in adults aged 18 to 64 that found that the long-acting under-the-skin treatment met efficacy and safety goals with results in line with oral version of the same drug, the company said.The experimental injection uses Medincell's SteadyTeq technology to deliver a steady monthly dose of olanzapine, Teva said.Shares of the company were up 1.7% in recent Tuesday trading.Price: 28.77, Change: +0.44, Percent Change: +1.54","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4596":"哈里斯概念","BK4559":"巴菲特持仓","BK4584":"避孕概念","BK4007":"制药","BK4566":"资本集团","BK4588":"碎股","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4557":"大麻股","TEVA":"梯瓦制药"},"translate_title":"梯瓦制药向FDA提交每月精神分裂症治疗申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5},"content_text":"Teva Pharmaceuticals (TEVA) said Tuesday it has submitted a new drug application to the US Food and Drug Administration of its once-monthly olanzapine extended-release injection, TEV-749, to treat schizophrenia in adults.The application is based on a phase 3 study in adults aged 18 to 64 that found that the long-acting under-the-skin treatment met efficacy and safety goals with results in line with oral version of the same drug, the company said.The experimental injection uses Medincell's SteadyTeq technology to deliver a steady monthly dose of olanzapine, Teva said.Shares of the company were up 1.7% in recent Tuesday trading.Price: 28.77, Change: +0.44, Percent Change: +1.54","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590534058","isCrawlerRequest":true}